IBDEI1F5 ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,22949,1,3,0)
 ;;=3^S/P Non-Melanoma Skin Cancer
 ;;^UTILITY(U,$J,358.3,22949,1,4,0)
 ;;=4^Z85.828
 ;;^UTILITY(U,$J,358.3,22949,2)
 ;;=^5063443
 ;;^UTILITY(U,$J,358.3,22950,0)
 ;;=Z85.820^^76^992^2
 ;;^UTILITY(U,$J,358.3,22950,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22950,1,3,0)
 ;;=3^S/P Melanoma
 ;;^UTILITY(U,$J,358.3,22950,1,4,0)
 ;;=4^Z85.820
 ;;^UTILITY(U,$J,358.3,22950,2)
 ;;=^5063441
 ;;^UTILITY(U,$J,358.3,22951,0)
 ;;=L57.8^^76^992^3
 ;;^UTILITY(U,$J,358.3,22951,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22951,1,3,0)
 ;;=3^Actinic Damage
 ;;^UTILITY(U,$J,358.3,22951,1,4,0)
 ;;=4^L57.8
 ;;^UTILITY(U,$J,358.3,22951,2)
 ;;=^5009226
 ;;^UTILITY(U,$J,358.3,22952,0)
 ;;=L57.0^^76^992^4
 ;;^UTILITY(U,$J,358.3,22952,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22952,1,3,0)
 ;;=3^Actinic Keratosis
 ;;^UTILITY(U,$J,358.3,22952,1,4,0)
 ;;=4^L57.0
 ;;^UTILITY(U,$J,358.3,22952,2)
 ;;=^66900
 ;;^UTILITY(U,$J,358.3,22953,0)
 ;;=D48.5^^76^992^5
 ;;^UTILITY(U,$J,358.3,22953,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22953,1,3,0)
 ;;=3^Neoplasm of Uncertain Behavior
 ;;^UTILITY(U,$J,358.3,22953,1,4,0)
 ;;=4^D48.5
 ;;^UTILITY(U,$J,358.3,22953,2)
 ;;=^267777
 ;;^UTILITY(U,$J,358.3,22954,0)
 ;;=L82.1^^76^992^6
 ;;^UTILITY(U,$J,358.3,22954,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22954,1,3,0)
 ;;=3^Seborrheic Keratosis
 ;;^UTILITY(U,$J,358.3,22954,1,4,0)
 ;;=4^L82.1
 ;;^UTILITY(U,$J,358.3,22954,2)
 ;;=^303312
 ;;^UTILITY(U,$J,358.3,22955,0)
 ;;=L82.0^^76^992^7
 ;;^UTILITY(U,$J,358.3,22955,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22955,1,3,0)
 ;;=3^Inflamed Seborrheic Keratosis
 ;;^UTILITY(U,$J,358.3,22955,1,4,0)
 ;;=4^L82.0
 ;;^UTILITY(U,$J,358.3,22955,2)
 ;;=^303311
 ;;^UTILITY(U,$J,358.3,22956,0)
 ;;=B07.9^^76^992^8
 ;;^UTILITY(U,$J,358.3,22956,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22956,1,3,0)
 ;;=3^Viral Wart
 ;;^UTILITY(U,$J,358.3,22956,1,4,0)
 ;;=4^B07.9
 ;;^UTILITY(U,$J,358.3,22956,2)
 ;;=^5000519
 ;;^UTILITY(U,$J,358.3,22957,0)
 ;;=D22.9^^76^992^9
 ;;^UTILITY(U,$J,358.3,22957,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22957,1,3,0)
 ;;=3^Mole/Melanocytic
 ;;^UTILITY(U,$J,358.3,22957,1,4,0)
 ;;=4^D22.9
 ;;^UTILITY(U,$J,358.3,22957,2)
 ;;=^5002058
 ;;^UTILITY(U,$J,358.3,22958,0)
 ;;=D23.9^^76^992^10
 ;;^UTILITY(U,$J,358.3,22958,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22958,1,3,0)
 ;;=3^Benign Neoplasm
 ;;^UTILITY(U,$J,358.3,22958,1,4,0)
 ;;=4^D23.9
 ;;^UTILITY(U,$J,358.3,22958,2)
 ;;=^5002076
 ;;^UTILITY(U,$J,358.3,22959,0)
 ;;=D18.01^^76^992^11
 ;;^UTILITY(U,$J,358.3,22959,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22959,1,3,0)
 ;;=3^Angioma
 ;;^UTILITY(U,$J,358.3,22959,1,4,0)
 ;;=4^D18.01
 ;;^UTILITY(U,$J,358.3,22959,2)
 ;;=^267697
 ;;^UTILITY(U,$J,358.3,22960,0)
 ;;=L24.89^^76^992^12
 ;;^UTILITY(U,$J,358.3,22960,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22960,1,3,0)
 ;;=3^Irritant Dermatitis
 ;;^UTILITY(U,$J,358.3,22960,1,4,0)
 ;;=4^L24.89
 ;;^UTILITY(U,$J,358.3,22960,2)
 ;;=^5009135
 ;;^UTILITY(U,$J,358.3,22961,0)
 ;;=L21.8^^76^992^13
 ;;^UTILITY(U,$J,358.3,22961,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22961,1,3,0)
 ;;=3^Seborrheic Dermatitis
 ;;^UTILITY(U,$J,358.3,22961,1,4,0)
 ;;=4^L21.8
 ;;^UTILITY(U,$J,358.3,22961,2)
 ;;=^303310
 ;;^UTILITY(U,$J,358.3,22962,0)
 ;;=L20.89^^76^992^14
 ;;^UTILITY(U,$J,358.3,22962,1,0)
 ;;=^358.31IA^4^2
